Current Treatment Options in Oncology

, Volume 8, Issue 6, pp 428–434 | Cite as

Angiosarcomas and Taxanes

  • Nicolas Penel
  • Amélie Lansiaux
  • Antoine Adenis
Soft Tissue

Opinion statement

Angiosarcomas (AS) are a heterogeneous group of rare and aggressive malignancies. The best treatment of localized AS includes wide resection following by adjuvant radiation therapy as possible. The current standard treatment of metastatic AS remains a doxorubicin-based regimen. This treatment provides a median progression-free survival and a median overall survival of about 4 and 8 months, respectively. Numerous case reports and retrospective studies have suggested that taxanes (paclitaxel or docetaxel) may provide some objective responses. The French Sarcoma Group has conducted a phase II clinical trial, which states the benefit of weekly paclitaxel in patients with unresectable or metastatic AS. After 2 cycles, the non-progression rate was 78% and complete histological responses were observed in 3 out of 30 cases. Further clinical studies are needed to confirm clinic impact of weekly paclitaxel on survival and to assess the role of taxanes in the multidisciplinary treatment of AS.


Paclitaxel Docetaxel Clin Oncol Sorafenib Taxanes 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.



The authors specially thank the members of the “Bureau des Etudes Cliniques de la FNCLCC” (Marta JIMENEZ, Céline MAHIER, Jean GENEVE) and the members of the Groupe Sarcome Français (GSF/GETO) for their help in the management of the Angio-Tax Study.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: •Of importance ••Of major importance

  1. 1.
    Hodden CA, Spittle MF, Jones EW: Angiosarcoma of the face and scalp: prognosis and treatment. Cancer 1987, 59:1046CrossRefGoogle Scholar
  2. 2.
    Coindre JM, Terrier P, Guillou L, et al.: Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas. Cancer 2001, 91:1914–1926CrossRefPubMedGoogle Scholar
  3. 3.
    Fury MG, Antonescu CR, Van Zee KJ, Brennan MF, Maki RG: A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J 2005, 11:241–247CrossRefPubMedGoogle Scholar
  4. 4.
    Penel N, Depadt G, Vilain M-O, et al.: Fréquence des génopathies et des antécédents carcinologiques chez 493 adultes atteints de sarcomes viscéraux ou des tissus mous. Bull Cancer 2003, 90:887–895PubMedGoogle Scholar
  5. 5.•
    Fata F, O’Reilly E, Ilson D, Pfister D, et al.: Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 1999, 86:2034–2037Google Scholar

This is the first “large” retrospective case reports which suggest a potential efficacy of paclitaxel in angiosarcomas of scalp and face. The response rate was 8/9 patients.

  1. 6.
    Mark RJ, Poen JC, Tran LM, Fu YS, Juillard GF: Angiosarcoma. A report of 67 patients and review of the literature. Cancer 1996, 77:2400–2406CrossRefPubMedGoogle Scholar
  2. 7.
    Fodor J, Orosz Z, Szabo E, et al.: Angiosarcoma after conservation treatment for breast carcinoma: our experience and review of the literature. J Am Acad Dermatol 2006, 54:499–504CrossRefPubMedGoogle Scholar
  3. 8.
    Zelek L, Llombart-Cussac A, Terrier P, et al.: Prognostic factors in primary breast sarcomas: a series of patients with long-term follow-up. J Clin Oncol 2003, 21:2583–2588CrossRefPubMedGoogle Scholar
  4. 9.
    Nanus DM, Kelsen D, Clark DG: Radiation-induced angiosarcoma. Cancer 1987, 60:777–779CrossRefPubMedGoogle Scholar
  5. 10.
    Heath CW Jr, Falk H, Creech JL Jr: Characteristics of cases of angiosarcoma of the liver among vinyl chloride workers in the United States. Ann NY Acad Sci 1975, 246:231–236CrossRefPubMedGoogle Scholar
  6. 11.
    Makk L, Delmore F, Creech JL: Angiosarcomas of the liver in workers having prolonged contact with vinyl chloride: epidemiology and program of research in the workers. Union Med Can 1975, 104:1833–1835PubMedGoogle Scholar
  7. 12.
    Donnell RM, Rosen PP, Lieberman PH, et al.: Angiosarcoma and other vascular tumors of the breast: pathologic analysis as a guide to prognosis. Am J Surg Pathol 1981, 5:629–642PubMedCrossRefGoogle Scholar
  8. 13.
    Vorburger SA, Xing Y, Hunt KK, et al.: Angiosarcoma of the breast. Cancer 2005, 104:2882–2888CrossRefGoogle Scholar
  9. 14.
    Morgan MB, Swann M, Somach S, et al.: Cutaneous angiosarcoma: a case series with prognosis correlation. J Am Acad Dermatol 2004, 50:867–874CrossRefPubMedGoogle Scholar
  10. 15.
    Pawlik TM, Paulino AF, McGinn CJ, et al.: Cutaneous angiosarcoma of the scalp: a multidisciplinary approach. Cancer 2003, 98:1716–1726CrossRefPubMedGoogle Scholar
  11. 16.
    Naka N, Oshawa M, Tomiat Y, et al.: Prognostic factors in angiosarcoma: a multivariate analysis of 55 cases. J Surg Oncol 1996, 61:170–176CrossRefPubMedGoogle Scholar
  12. 17.
    Tomascello L, Gardin G, Boccardo F: Secondary breast angiosarcoma: lethal response to antiangiogenic therapy with paclitaxel chemotherapy. A case report. Anticancer Res 2006, 26:4775–4777Google Scholar
  13. 18.
    Skubitz KM, Haddad PA: Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer 2005, 104:361–366CrossRefPubMedGoogle Scholar
  14. 19.
    Pestoni C, Paredes-Suarez C, Peteir C, Toribio J: Early detection of cutaneous angiosarcoma of the face and treatment with paclitaxel. J Eur Acad Dermatol Venereol 2005, 19:357–359CrossRefPubMedGoogle Scholar
  15. 20.
    Veliz M, Chang V, Kasimis B, Choe JK: Durable response of angiosarcoma of the face and scalp to docetaxel. Clin Oncol (R Coll Radiol) 2007, 19:210Google Scholar
  16. 21.
    Yamada M, Hatta N, Mizuno M, Oishi N, Takehara K: Weekly low-dose docetaxel in the treatment of lung metastases from angiosarcoma of the head. Br J Dermatol 2005, 152:811–812CrossRefPubMedGoogle Scholar
  17. 22.
    Isogai R, Kawada A, Aragane Y, Tezuka T: Successful treatment of pulmonary metastasis and local recurrence of angiosarcoma with docetaxel. J Dermatol 2004, 31:335–341PubMedGoogle Scholar
  18. 23.
    Mano MS, Fraser G, et al.: Radiation-induced angiosarcoma f the breast shows major response to docetaxel after failure of anthracycline-based chemotherapy. Breast 2006, 15:117–118CrossRefPubMedGoogle Scholar
  19. 24.
    Schlemmer M, Reichardt P, et al.: Paclitaxel in patients (pts) with advanced angiosarcomas (Abstract 10033). J Clin Oncol 2007, 25:553SGoogle Scholar
  20. 25.••
    Penel N, Bui Nguyen B, Bay JO, et al.: Weekly paclitaxel in metastatic angiosarcoma. A FNCLCC French Sarcoma Group (GSF-GETO) phase II trial (Abstract 10002). J Clin Oncol 2007, 25:545sGoogle Scholar

This is the first clinical trial evaluating a chemotherapy regimen in patients with angiosarcomas. This phase II trial clearly establishes a non-progression of 78% after 2 cycles and an overall survival of 7.6 months. Two histological complete responses were observed.

  1. 26.
    Amo Y, Masuzawa M, Hamada Y, Katsouka K: Expression of vascular endothelial growth factor in a human hemangiosarcoma cell line (ISO-HAS). Arch Dermatol Res 2001, 293:296–301CrossRefPubMedGoogle Scholar
  2. 27.
    Naito S, Shimizu K, Nakashima M, et al.: Overexpression of Ets-1 transcription factor in angiosarcoma of the skin. Pathol Res Pract 2000, 196:103–109PubMedGoogle Scholar
  3. 28.
    Zietz C, Rossle M, Hass C, et al.: MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am J Pathol 1998, 153:1425–1433PubMedGoogle Scholar
  4. 29.
    Raina V, Sengar M, Shukla NK, et al.: Complete response from thalidomide in angiosarcoma after treatment of breast cancer. J Clin Oncol 2007, 25:900–901CrossRefPubMedGoogle Scholar
  5. 30.
    D’Adamo DR, Keohan M, Schuetze S, et al.: Clinical results of a phase II study of sorafenib in patients (pts) with non-GIST sarcomas (CTEP study #7060). (Abstract 10001). J Clin Oncol 2007, 25:545sGoogle Scholar
  6. 31.
    Stebbing J, Wildfire A, Portsmouth S, et al.: Paclitaxel for anthracyclin-resistant AIDS-related Kaposi’s sarcoma: clinical and angiogenic correlations. Ann Oncol 2003, 14:1660–1666CrossRefPubMedGoogle Scholar
  7. 32.
    Pasquier E, Honore S, Pourroy B, et al.: Antiangiogenic concentrations of pacliatxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res 2005, 65:2433–2440CrossRefPubMedGoogle Scholar
  8. 33.
    Merchan JR, Jayaram DR, Supko JG, He X, Bubley GJ, Sukhatme VP: Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition. Int J Cancer 2005, 113:490–498CrossRefPubMedGoogle Scholar
  9. 34.
    Jordan MA, Toso RJ, Thrower D, Wilson L.: Mechanism of mitotic block and inhibition cell proliferation by taxol at low concentrations. Proc Natl Acad Sci 1993, 90:9552–9556CrossRefPubMedGoogle Scholar
  10. 35.•
    Pasquier E, Carre M, Pourroy B, et al.: Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptosis signaling pathway. Mol Cancer Ther 2004, 3:1301–1310Google Scholar

This preclinical study explores the anti-angiogenic activity of low dose of paclitaxel. These findings suggest an induction of apoptosis via mitochondrial signaling pathway.

  1. 36.
    Pivot X, Chevreau C, Cupissol D, et al.: Phase II trial of paclitaxel-epirubicin in patients wit recurrent soft tissue sarcoma. Am J Clin Oncol 2002, 25:661–664CrossRefGoogle Scholar
  2. 37.
    Köstler WJ, Brodowicz T, Attems Y, et al.: Docetaxel as rescue medication in anthracyclines- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial. Ann Oncol 2001, 12:1281–1288CrossRefPubMedGoogle Scholar
  3. 38.
    Verweij J, Lee SM, Ruka W, et al.: Randomized phase II study of docetaxel versus doxorubicin in first-line and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the European Organization of Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000, 18:2081–2086PubMedGoogle Scholar
  4. 39.
    Enzinger FM, Weiss SW. Malignant vascular tumors. In Soft Tissue Tumors, Third Edition. Edited by Enzinger FM, Weiss SW. Saint-Louis Missouri: Mosby; 1995:641–678Google Scholar
  5. 40.
    Givens SS, Ellebrocck MA, Butler JJ, et al.: Angiosarcoma arising in an irradiated breast. A case review of the literature. Cancer 1989, 64:2214–2216CrossRefPubMedGoogle Scholar

Copyright information

© Current Science Inc. 2007

Authors and Affiliations

  • Nicolas Penel
    • 1
    • 2
  • Amélie Lansiaux
    • 3
  • Antoine Adenis
    • 4
  1. 1.Département de Cancérologie GénéraleCentre Oscar LambretLilleFrance
  2. 2.Equipe d’Accueil 2694: Santé Publique, Epidémiologie et modélisation des maladies chroniquesUniversité Lille IILilleFrance
  3. 3.Laboratoire de Pharmacologie Anti-tumoraleCentre Oscar LambretLilleFrance
  4. 4.Département de Cancérologie Digestive et UrologiqueCentre Oscar LambretLilleFrance

Personalised recommendations